Skip to main content

Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Publication ,  Journal Article
Clarke, JM; Hurwitz, HI
Published in: Expert Opin Biol Ther
August 2013

INTRODUCTION: Ramucirumab (IMC-1121B) is a fully humanized IgG1 monoclonal antibody, targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I - II trials in various malignancies have shown promising clinical antitumor efficacy and tolerability. Most recently, the large Phase III REGARD trial evaluated ramucirumab in patients with refractory metastatic gastric cancer. Patients receiving ramucirumab experienced a median overall survival of 5.2 months compared to 3.8 months on placebo. AREAS COVERED: The purpose of this article is to review the preclinical motivation for VEGFR2-targeted therapies and survey recent data from clinical trials involving ramucirumab, as well as highlight ongoing studies. EXPERT OPINION: Rational multi-target approaches to angiogenesis are needed to overcome resistance mechanisms. Predictive angiogenic biomarkers are also needed to optimize patient selection for novel anti-angiogenic agents.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

August 2013

Volume

13

Issue

8

Start / End Page

1187 / 1196

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-2
  • Ramucirumab
  • Neoplasms
  • Immunology
  • Humans
  • Clinical Trials as Topic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Animals
  • 3206 Medical biotechnology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clarke, J. M., & Hurwitz, H. I. (2013). Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther, 13(8), 1187–1196. https://doi.org/10.1517/14712598.2013.810717
Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Expert Opin Biol Ther 13, no. 8 (August 2013): 1187–96. https://doi.org/10.1517/14712598.2013.810717.
Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013 Aug;13(8):1187–96.
Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Expert Opin Biol Ther, vol. 13, no. 8, Aug. 2013, pp. 1187–96. Pubmed, doi:10.1517/14712598.2013.810717.
Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013 Aug;13(8):1187–1196.

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

August 2013

Volume

13

Issue

8

Start / End Page

1187 / 1196

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-2
  • Ramucirumab
  • Neoplasms
  • Immunology
  • Humans
  • Clinical Trials as Topic
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Animals
  • 3206 Medical biotechnology